Japan Government Failures Hamper Medical Innovation, Ex-Official Says
This article was originally published in PharmAsia News
Failures by the Japanese government have made it incapable of making proper evaluations of university research that could lead to medical innovations, according to a former Cabinet officer and cancer researcher.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.